PL2307454T3 - Trwałe i rozpuszczalne przeciwciała hamujące VEGF - Google Patents

Trwałe i rozpuszczalne przeciwciała hamujące VEGF

Info

Publication number
PL2307454T3
PL2307454T3 PL09768693T PL09768693T PL2307454T3 PL 2307454 T3 PL2307454 T3 PL 2307454T3 PL 09768693 T PL09768693 T PL 09768693T PL 09768693 T PL09768693 T PL 09768693T PL 2307454 T3 PL2307454 T3 PL 2307454T3
Authority
PL
Poland
Prior art keywords
stable
inhibiting vegf
soluble antibodies
antibodies inhibiting
soluble
Prior art date
Application number
PL09768693T
Other languages
English (en)
Inventor
Leonardo Borras
David Urech
Tea Gunde
Original Assignee
Esbatech, An Alcon Biomedical Research Unit Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech, An Alcon Biomedical Research Unit Llc filed Critical Esbatech, An Alcon Biomedical Research Unit Llc
Publication of PL2307454T3 publication Critical patent/PL2307454T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PL09768693T 2008-06-25 2009-06-25 Trwałe i rozpuszczalne przeciwciała hamujące VEGF PL2307454T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7569208P 2008-06-25 2008-06-25
US13321208P 2008-06-25 2008-06-25
US7569708P 2008-06-25 2008-06-25
US15504109P 2009-02-24 2009-02-24
EP09768693.5A EP2307454B1 (en) 2008-06-25 2009-06-25 Stable and soluble antibodies inhibiting vegf

Publications (1)

Publication Number Publication Date
PL2307454T3 true PL2307454T3 (pl) 2017-07-31

Family

ID=41209803

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17151756T PL3216803T3 (pl) 2008-06-25 2009-06-25 Stabilne i rozpuszczalne przeciwciała hamujące vegf
PL09768693T PL2307454T3 (pl) 2008-06-25 2009-06-25 Trwałe i rozpuszczalne przeciwciała hamujące VEGF

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17151756T PL3216803T3 (pl) 2008-06-25 2009-06-25 Stabilne i rozpuszczalne przeciwciała hamujące vegf

Country Status (26)

Country Link
US (5) US8349322B2 (pl)
EP (3) EP3216803B1 (pl)
JP (7) JP5956752B2 (pl)
KR (8) KR102095257B1 (pl)
CN (3) CN104961828B (pl)
AU (1) AU2009264565C1 (pl)
BR (1) BRPI0914251B1 (pl)
CA (2) CA3020290A1 (pl)
CL (1) CL2010001544A1 (pl)
CY (3) CY1118829T1 (pl)
DK (2) DK3216803T3 (pl)
ES (2) ES2793008T3 (pl)
HK (1) HK1150844A1 (pl)
HR (2) HRP20170615T1 (pl)
HU (3) HUE050230T2 (pl)
LT (3) LT2307454T (pl)
MX (2) MX2011000011A (pl)
NL (1) NL301058I2 (pl)
NO (1) NO2020021I1 (pl)
PH (1) PH12015501593A1 (pl)
PL (2) PL3216803T3 (pl)
PT (2) PT2307454T (pl)
RU (6) RU2531523C3 (pl)
SI (2) SI2307454T1 (pl)
WO (1) WO2009155724A2 (pl)
ZA (1) ZA201008594B (pl)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710645A2 (pt) 2006-04-07 2012-03-20 The Procter & Gamble Company Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
CN102076716A (zh) 2008-06-25 2011-05-25 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 抑制TNFα的稳定和可溶的抗体
JP5856480B2 (ja) 2008-06-25 2016-02-09 エスバテック − ア ノバルティスカンパニー エルエルシー 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化
KR102095257B1 (ko) 2008-06-25 2020-04-01 노바르티스 아게 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
RU2582244C2 (ru) * 2008-06-30 2016-04-20 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Функционализированные полипептиды
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CN102239181A (zh) 2009-02-24 2011-11-09 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 用于鉴定细胞表面抗原的免疫结合剂的方法
EA020621B1 (ru) 2009-06-22 2014-12-30 Амген Инк. Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
WO2010151688A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
CN103429260B (zh) * 2010-10-19 2016-08-10 梅奥医学教育和研究基金会 用于治疗神经疾病的人抗体及其诊断和治疗用途
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
HUE043661T2 (hu) * 2011-09-16 2019-08-28 Ucb Biopharma Sprl A Clostridium difficile TCDA és TCDB exotoxinjai elleni semlegesítõ ellenanyagok
WO2013113820A1 (en) 2012-02-02 2013-08-08 Esbatech - A Novartis Company Llc Antibody-containing sustained-release formulation for ocular administration
CN104428315B (zh) 2012-07-13 2017-09-29 罗氏格黎卡特股份公司 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用
AU2013362909A1 (en) 2012-12-18 2015-05-21 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
WO2014124487A1 (en) 2013-02-18 2014-08-21 Vegenics Pty Limited Ligand binding molecules and uses thereof
KR101541478B1 (ko) * 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
JP6708544B2 (ja) * 2013-06-26 2020-06-10 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗体フレームワーク
KR20230152151A (ko) 2013-07-12 2023-11-02 이베릭 바이오, 인크. 안과적 질환을 치료하거나 예방하기 위한 방법
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
EP3492495A1 (en) 2014-05-12 2019-06-05 Formycon AG Pre-filled plastic syringe containing a vegf antagonist
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
KR102390359B1 (ko) 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US10093730B2 (en) 2014-11-10 2018-10-09 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
MX2017009759A (es) * 2015-01-28 2017-10-27 Pfizer Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
TWI721975B (zh) 2015-04-16 2021-03-21 美商艾爾德生物製藥股份有限公司 抗ｐａｃａｐ抗體及其用途
US10851399B2 (en) * 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
ES2913530T3 (es) 2015-08-12 2022-06-02 Novartis Ag Métodos para tratar trastornos oftálmicos
MX2018004509A (es) 2015-10-30 2018-08-01 Genentech Inc Anticuerpos anti-htra1 y metodos de uso de los mismos.
US11136609B2 (en) * 2015-11-09 2021-10-05 National University Corporation Kyoto Institute Of Technology Separating agent for human serum-derived IgG polyclonal antibodies, and method for separating human serum-derived IgG polyclonal antibodies using same
WO2017085253A1 (en) 2015-11-18 2017-05-26 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
RU2734958C2 (ru) 2015-11-18 2020-10-26 Формикон Аг Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
JP7430485B2 (ja) 2015-11-18 2024-02-13 エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド 眼科用製剤のための薬剤パッケージ
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
JP6910963B2 (ja) 2016-01-06 2021-07-28 株式会社オーダーメードメディカルリサーチ 高親和性抗ｖｅｇｆ抗体
EP3401330A4 (en) 2016-01-06 2019-09-18 Order-Made Medical Research Inc. ANTIBODY-BINDING BINDING BETWEEN VEGF AND NRP1
USD789171S1 (en) 2016-01-21 2017-06-13 Nomis Llc Right angle drive
JP6953433B2 (ja) 2016-01-26 2021-10-27 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆアンタゴニストを含む液体医薬組成物および同医薬組成物を含有する充填済みシリンジ
AU2017214685B2 (en) * 2016-02-05 2024-03-07 The Board Of Regents Of The University Of Texas System EGFL6 specific monoclonal antibodies and methods of their use
WO2017156423A2 (en) * 2016-03-11 2017-09-14 Integrated Biotherapeutics, Inc. Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
EP3222673A1 (de) * 2016-03-23 2017-09-27 LANXESS Deutschland GmbH Metallazopigmente
AU2017250807A1 (en) * 2016-04-15 2018-10-25 H. Lundbeck A/S. Anti-PACAP antibodies and uses thereof
PE20190448A1 (es) 2016-06-30 2019-03-29 Celltrion Inc Formulacion farmaceutica liquida estable
WO2018009939A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
CN110382002A (zh) * 2017-03-09 2019-10-25 Mab发现股份有限公司 特异性结合人il-1r7的抗体
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
BR112019023795A2 (pt) 2017-05-19 2020-07-28 Council Of Scientific & Industrial Research método para produzir ranibizumabe humanizado recombinante redobrado
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
CA3063995A1 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
KR20200092302A (ko) * 2017-06-25 2020-08-03 시스트이뮨, 인코포레이티드 다중-특이적 항체 및 이들의 제조 및 사용 방법
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
JP7184894B2 (ja) 2017-11-27 2022-12-06 ４ディー モレキュラー セラピューティクス インコーポレイテッド アデノ随伴ウイルス変異キャプシドおよび血管新生の阻害のための使用
EP3731864A1 (en) * 2017-12-29 2020-11-04 F. Hoffmann-La Roche SA Anti-vegf antibodies and methods of use
EP3740509A4 (en) * 2018-01-17 2022-06-22 Apexigen, Inc. ANTI-PD-L1 ANTIBODIES AND METHODS OF USE
MX2020009140A (es) 2018-03-16 2020-09-28 Novartis Ag Metodos para el tratamiento de enfermedades oculares.
EP3773914A1 (en) * 2018-04-06 2021-02-17 Eli Lilly and Company Ramucirumab for the treatment of cancers in pediatric patients
JP7397874B2 (ja) 2018-08-30 2023-12-13 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
SG11202101780WA (en) 2018-08-30 2021-03-30 Hcw Biologics Inc Single-chain chimeric polypeptides and uses thereof
CA3109361A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES TARGETING HPTP-ß (VE-PTP) AND VEGF
JP7089121B2 (ja) 2018-12-18 2022-06-21 ノバルティス アーゲー 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤
USD907456S1 (en) 2019-05-21 2021-01-12 Nomis Llc Right angle drill attachment
USD907455S1 (en) 2019-05-21 2021-01-12 Nomis Llc Right angle drive attachment
AU2020294797A1 (en) 2019-06-21 2021-12-23 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
JP2022547537A (ja) 2019-09-13 2022-11-14 ノバルティス アーゲー 眼疾患を治療するための方法
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
WO2021163299A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Chromatography resin and uses thereof
AU2021220870A1 (en) 2020-02-11 2022-08-04 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
WO2021163298A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
EP4110819A1 (en) * 2020-02-28 2023-01-04 Apexigen, Inc. Anti-sirpa antibodies and methods of use
BR112022018088A2 (pt) * 2020-03-12 2023-01-17 Immune Onc Therapeutics Inc Novos anticorpos anti-lilrb4 e produtos derivados
MX2022011156A (es) 2020-03-13 2022-10-13 Genentech Inc Anticuerpos anti-interleucina-33 y usos de estos.
EP4143231A1 (en) 2020-04-29 2023-03-08 HCW Biologics, Inc. Anti-cd26 proteins and uses thereof
IL298608A (en) 2020-06-01 2023-01-01 Hcw Biologics Inc Methods for treating disorders related to aging
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
EP4182025A1 (en) 2020-07-16 2023-05-24 Novartis AG Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
JP2023546112A (ja) 2020-10-15 2023-11-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 長時間作用型眼送達用非共有結合タンパク質－ヒアルロナンコンジュゲート
TW202237181A (zh) 2020-11-25 2022-10-01 瑞士商諾華公司 治療眼部疾病之方法
WO2022201084A1 (en) 2021-03-26 2022-09-29 Novartis Ag Methods for treating ocular diseases
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
KR20230094450A (ko) 2021-12-21 2023-06-28 한림대학교 산학협력단 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
WO2023168363A1 (en) 2022-03-02 2023-09-07 HCW Biologics, Inc. Method of treating pancreatic cancer
TW202337496A (zh) 2022-03-17 2023-10-01 瑞士商諾華公司 治療新生血管性年齡相關性黃斑點退化之方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
OA10149A (en) 1991-03-29 1996-12-18 Genentech Inc Vascular endothelial cell growth factor antagonists
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP1167384B1 (en) 1992-10-28 2006-12-13 Genentech, Inc. HVEGF Receptor as Vascular endothelial cell growth factor antagonists
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
CZ292465B6 (cs) 1996-02-09 2003-09-17 Abbott Laboratories (Bermuda) Ltd. Lidské protilátky k lidskému TNFalfa
EP0938506B1 (en) * 1996-07-16 2003-11-05 Plückthun, Andreas, Prof. Dr. Immunoglobulin superfamily domains and fragments with increased solubility
WO2000053760A2 (en) 1999-03-12 2000-09-14 Genentech, Inc. Method of preventing the death of retinal neurons and treating ocular diseases
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
CA2286330C (en) * 1997-04-07 2008-06-10 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
EP3260468A1 (en) * 1997-04-07 2017-12-27 Genentech, Inc. Anti-vegf antibodies
WO2000034337A1 (en) * 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
CN101073668A (zh) 1999-04-28 2007-11-21 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
JP2003527334A (ja) * 1999-10-22 2003-09-16 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ａ３３抗原特異的免疫グロブリン産物を用いるａ３３抗原を発現する癌の影響を低減する方法
WO2001048017A1 (en) 1999-12-28 2001-07-05 Esbatech Ag Intrabodies with defined framework that is stable in a reducing environment and applications thereof
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
DE10201450B4 (de) 2002-01-16 2004-09-02 Infineon Technologies Ag Carry-Skip-Addierer für verschlüsselte Daten
US6576941B1 (en) 2002-02-20 2003-06-10 Samsung Electronics Co., Ltd. Ferroelectric capacitors on protruding portions of conductive plugs having a smaller cross-sectional size than base portions thereof
CN1187373C (zh) * 2002-03-20 2005-02-02 上海中信国健药业有限公司 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物
CN1305905C (zh) 2002-03-22 2007-03-21 Aprogen株式会社 人源化抗体及其制备方法
US8853362B2 (en) 2002-05-22 2014-10-07 Esbatech, An Alcon Biomedical Research Unit Llc Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
JP2005535341A (ja) * 2002-08-15 2005-11-24 エピトミスク インコーポレーティッド ヒト化ウサギ抗体
CN101274098A (zh) 2003-05-30 2008-10-01 健泰科生物技术公司 利用抗-vegf抗体的治疗
US20050048578A1 (en) 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EP1651659A4 (en) * 2003-08-07 2008-09-17 Epitomics Inc METHOD FOR HUMANIZATION OF MONOCLONAL RABBIT ANTIBODIES
PL1781321T3 (pl) 2004-08-02 2014-07-31 Zenyth Operations Pty Ltd Sposób leczenia raka zawierający antagonistę VEGF-B
WO2006047325A1 (en) 2004-10-21 2006-05-04 Genentech, Inc. Method for treating intraocular neovascular diseases
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
AU2006281980A1 (en) * 2005-08-15 2007-02-22 Cephalon Australia Pty Ltd Engineered antibodies with new world primate framework regions
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007140534A1 (en) * 2006-06-08 2007-12-13 Csl Limited Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
SI2046382T1 (sl) 2006-07-10 2016-12-30 ESBATech an Alcon Biomedical Research Unit LLC Protitelesa scFv, ki prehajajo epitelijske in/ali endotelijske plasti
WO2008063932A2 (en) 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
US7553486B2 (en) 2006-11-13 2009-06-30 Paul Theodore Finger Anti-VEGF treatment for radiation-induced vasculopathy
KR20140148491A (ko) 2006-12-19 2014-12-31 제넨테크, 인크. 조기 종양의 치료 및 아주반트 및 네오아주반트 요법을 위한 ｖｅｇｆ－특이적 길항제
CN101668771B (zh) 2007-03-12 2013-08-21 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的工程改造和最优化
BRPI0812398A2 (pt) 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
CA2688434A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
RU2540150C2 (ru) 2007-06-25 2015-02-10 Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк Способы модификации антител и модифицированные антитела с улучшенными функциональными свойствами
WO2009000098A2 (en) 2007-06-25 2008-12-31 Esbatech Ag Sequence based engineering and optimization of single chain antibodies
CA3053675A1 (en) * 2008-03-26 2009-10-01 Epitomics, Inc. Anti-vegf antibody
KR102095257B1 (ko) 2008-06-25 2020-04-01 노바르티스 아게 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
JP5856480B2 (ja) 2008-06-25 2016-02-09 エスバテック − ア ノバルティスカンパニー エルエルシー 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化
AU2009264566B2 (en) 2008-06-25 2014-05-08 Novartis Ag Solubility optimization of immunobinders
CN104800147A (zh) * 2008-07-10 2015-07-29 德勒尼克斯治疗股份公司 用于大分子的增强的递送的方法和组合物
US8796425B2 (en) * 2009-12-23 2014-08-05 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity

Also Published As

Publication number Publication date
CL2010001544A1 (es) 2012-02-03
RU2648152C2 (ru) 2018-03-22
AU2009264565C1 (en) 2022-01-27
AU2009264565B2 (en) 2014-05-08
MX2011000011A (es) 2011-09-27
JP7171877B2 (ja) 2022-11-15
KR102296443B1 (ko) 2021-09-01
HUS2000028I1 (hu) 2020-08-28
RU2747735C3 (ru) 2022-05-04
CY2020026I1 (el) 2020-11-25
NL301058I1 (pl) 2020-07-31
JP6100199B2 (ja) 2017-03-22
CN104961828B (zh) 2019-03-26
JP2017055774A (ja) 2017-03-23
ZA201008594B (en) 2012-02-29
EP2307454A2 (en) 2011-04-13
US20140004114A1 (en) 2014-01-02
CY1123028T1 (el) 2021-10-29
JP2011525359A (ja) 2011-09-22
SI2307454T1 (sl) 2017-05-31
CA3020290A1 (en) 2009-12-30
EP3722310A1 (en) 2020-10-14
ES2622470T3 (es) 2017-07-06
RU2019120079A (ru) 2020-12-28
RU2016119152A (ru) 2017-11-21
LTC2307454I2 (lt) 2021-05-25
KR101817284B1 (ko) 2018-01-11
KR20200108922A (ko) 2020-09-21
CN110372792A (zh) 2019-10-25
RU2011102583A (ru) 2012-07-27
RU2019120079A3 (pl) 2020-12-28
RU2014132888A (ru) 2015-12-10
US9090684B2 (en) 2015-07-28
WO2009155724A2 (en) 2009-12-30
CY2020026I2 (el) 2020-11-25
KR20150132602A (ko) 2015-11-25
DK3216803T3 (da) 2020-06-02
KR101671886B1 (ko) 2016-11-04
KR102013220B1 (ko) 2019-08-23
KR102157097B1 (ko) 2020-09-18
HUE032894T2 (hu) 2017-11-28
CA2727839A1 (en) 2009-12-30
CN102143976B (zh) 2015-11-25
JP2022020782A (ja) 2022-02-01
RU2013133802A (ru) 2015-01-27
BRPI0914251A2 (pt) 2021-01-05
KR20180005753A (ko) 2018-01-16
RU2531523C9 (ru) 2015-04-10
HUE050230T2 (hu) 2020-11-30
JP6821612B2 (ja) 2021-01-27
US20180072802A1 (en) 2018-03-15
US20150274820A1 (en) 2015-10-01
RU2588467C3 (ru) 2021-10-20
PT3216803T (pt) 2020-06-16
KR20160128458A (ko) 2016-11-07
RU2531523C2 (ru) 2014-10-20
EP3216803B1 (en) 2020-03-11
CY1118829T1 (el) 2018-01-10
KR20110028518A (ko) 2011-03-18
JP2019162127A (ja) 2019-09-26
US10590193B2 (en) 2020-03-17
JP2014158491A (ja) 2014-09-04
ES2793008T3 (es) 2020-11-12
KR20180098705A (ko) 2018-09-04
HRP20200814T1 (hr) 2020-08-07
JP2018108081A (ja) 2018-07-12
PT2307454T (pt) 2017-04-26
NL301058I2 (nl) 2020-10-27
US9873737B2 (en) 2018-01-23
JP5956752B2 (ja) 2016-07-27
LTPA2020004I1 (lt) 2020-08-10
KR102095257B1 (ko) 2020-04-01
JP2015134792A (ja) 2015-07-27
US8349322B2 (en) 2013-01-08
KR20190092630A (ko) 2019-08-07
DK2307454T3 (en) 2017-04-24
JP6527128B2 (ja) 2019-06-05
EP3216803A1 (en) 2017-09-13
KR101737466B1 (ko) 2017-05-18
LT2307454T (lt) 2017-05-25
LT3216803T (lt) 2020-06-10
RU2747735C2 (ru) 2021-05-13
HRP20170615T1 (hr) 2017-07-28
JP7171877B6 (ja) 2024-02-06
SI3216803T1 (sl) 2020-07-31
NO2020021I1 (no) 2020-08-04
CA2727839C (en) 2018-11-20
CN102143976A (zh) 2011-08-03
HK1150844A1 (zh) 2012-01-13
US20200172608A1 (en) 2020-06-04
BRPI0914251B1 (pt) 2022-07-19
KR20170057462A (ko) 2017-05-24
AU2009264565A1 (en) 2009-12-30
RU2531523C3 (ru) 2022-05-04
MX347972B (es) 2017-05-22
RU2696972C1 (ru) 2019-08-07
JP6978468B2 (ja) 2021-12-08
PH12015501593A1 (en) 2015-12-14
PL3216803T3 (pl) 2020-10-19
CN104961828A (zh) 2015-10-07
US20120014958A1 (en) 2012-01-19
WO2009155724A3 (en) 2010-04-01
EP2307454B1 (en) 2017-01-18

Similar Documents

Publication Publication Date Title
HUS2000028I1 (hu) VEGF-gátló, stabilis és oldható antitestek
ZA201308787B (en) Stable and soluble antibodies inhibiting tnfa
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
IL216731A (en) And antibodies against p95 – her2 and their uses
ZA201102119B (en) Improved antibody libraies
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
PL2630159T3 (pl) Stabilne i rozpuszczalne przeciwciała
HK1195776A1 (zh) -α 抗-α 抗體及其應用
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
EP2388320A4 (en) ANTI-HS6ST2 ANTIBODIES AND USE THEREOF
IL214527A0 (en) Anti-mst1r antibodies and uses thereof
GB0812277D0 (en) Antibody and uses thereof
GB0911770D0 (en) Antibody
GB0906115D0 (en) Antibody and uses thereof
HUE036125T2 (hu) Stabil és oldható antitestek
GB0817622D0 (en) Antibody
GB0817621D0 (en) Antibody